Ming Huang

机构：Tianjin University of Traditional Chinese Medicine, Shenyang University of Technology, Sun Yat-sen University, Jinan University, Kunming Medical University, Sun Yat-sen Memorial Hospital, General Hospital of Shenyang Military Region, Shenyang University, Shenyang University of Chemical Technology, Fuzhou University · ORCID：0009-0006-0248-408X

发表论文 144 篇 · 总被引 5428 次 · h-index 31

代表论文

• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 45)
• An environmentally friendly, rainfall-resistant suspension prepared based on halloysite nanotubes for the delivery of hydrophobic pesticides (2024 · Chemical Engineering Journal · 被引 22)
• Single-Crystal Diamond Nanowires Embedded with Platinum Nanoparticles for High-Temperature Solar-Blind Photodetector (2025 · Nano-Micro Letters · 被引 21)
• Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) (2024 · Journal of Cachexia Sarcopenia and Muscle · 被引 14)
• Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, open-label, randomized, phase 2 study (CAP-ACE). (2025 · Journal of Clinical Oncology · 被引 13)
• Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study (2025 · MedComm · 被引 9)